Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 15 entries
Sorted by: Best Match Show Resources per page
[Genetic factors and colorectal cancers development: therapeutic impact].

Medecine sciences : M/S

Olschwang S, Viret F, Monges G, Seitz J, Sevenet N, Tiret E, Milano G, Birnbaum D, Bertucci F.
PMID: 16705943
Med Sci (Paris). 2006 Jan;22:45-9. doi: 10.1051/medsci/2006221s45.

Colorectal tumorigenesis is associated with the progressive increase of epithelium dysplasia and wall invasion. These criteria are evaluated through histological staging, that enables a reliable estimation of patient prognosis, and is the best tool for therapeutic decision. Adjuvant chemotherapy...

Cite
Olschwang S, Viret F, Monges G, et al. Identification des facteurs génétiques associés à l'évolution des cancers coliques: impact sur la prise en charge thérapeutique. [Genetic factors and colorectal cancers development: therapeutic impact]. Med Sci (Paris). 2006;22:45-9doi: 10.1051/medsci/2006221s45.
Olschwang, S., Viret, F., Monges, G., Seitz, J., Sevenet, N., Tiret, E., Milano, G., Birnbaum, D., & Bertucci, F. (2006). Identification des facteurs génétiques associés à l'évolution des cancers coliques: impact sur la prise en charge thérapeutique. [Genetic factors and colorectal cancers development: therapeutic impact]. Medecine sciences : M/S, 2245-9. https://doi.org/10.1051/medsci/2006221s45
Olschwang, Sylviane, et al. "Identification des facteurs génétiques associés à l'évolution des cancers coliques: impact sur la prise en charge thérapeutique." [Genetic factors and colorectal cancers development: therapeutic impact]. Medecine sciences : M/S vol. 22 (2006): 45-9. doi: https://doi.org/10.1051/medsci/2006221s45
Olschwang S, Viret F, Monges G, Seitz J, Sevenet N, Tiret E, Milano G, Birnbaum D, Bertucci F. Identification des facteurs génétiques associés à l'évolution des cancers coliques: impact sur la prise en charge thérapeutique. [Genetic factors and colorectal cancers development: therapeutic impact]. Med Sci (Paris). 2006 Jan;22:45-9. doi: 10.1051/medsci/2006221s45. French. PMID: 16705943.
Copy Download .nbib Format: NLM
[Chemotherapy of colorectal carcinoma].

Srpski arhiv za celokupno lekarstvo

Jelić S, Nikolić-Tomasević Z, Popov I, Radosavljević D.
PMID: 9921027
Srp Arh Celok Lek. 1998 Nov-Dec;126(11):506-11.

The benefit of adjuvant therapy in colorectal cancer (CRC) has been provided in clinical studies that have demonstrated reduction of up to 30% in a 5-year overall mortality in patients (pts.) with TNM stage III (Dukes' stage C) carcinoma....

Cite
Jelić S, Nikolić-Tomasević Z, Popov I, et al. Hemoterapija karcinoma kolorectuma. [Chemotherapy of colorectal carcinoma]. Srp Arh Celok Lek. 1998;126(11):506-11
Jelić, S., Nikolić-Tomasević, Z., Popov, I., & Radosavljević, D. (1998). Hemoterapija karcinoma kolorectuma. [Chemotherapy of colorectal carcinoma]. Srpski arhiv za celokupno lekarstvo, 126(11), 506-11.
Jelić, S, et al. "Hemoterapija karcinoma kolorectuma." [Chemotherapy of colorectal carcinoma]. Srpski arhiv za celokupno lekarstvo vol. 126,11 (1998): 506-11.
Jelić S, Nikolić-Tomasević Z, Popov I, Radosavljević D. Hemoterapija karcinoma kolorectuma. [Chemotherapy of colorectal carcinoma]. Srp Arh Celok Lek. 1998 Nov-Dec;126(11):506-11. Serbian. PMID: 9921027.
Copy Download .nbib Format: NLM
Issues remain for treating colorectal cancer.

Journal of the National Cancer Institute

Reynolds T.
PMID: 7707431
J Natl Cancer Inst. 1995 Apr 05;87(7):480. doi: 10.1093/jnci/87.7.480.

No abstract available.

Cite
Reynolds T. Issues remain for treating colorectal cancer. J Natl Cancer Inst. 1995;87(7):480doi: 10.1093/jnci/87.7.480.
Reynolds, T. (1995). Issues remain for treating colorectal cancer. Journal of the National Cancer Institute, 87(7), 480. https://doi.org/10.1093/jnci/87.7.480
Reynolds, T. "Issues remain for treating colorectal cancer." Journal of the National Cancer Institute vol. 87,7 (1995): 480. doi: https://doi.org/10.1093/jnci/87.7.480
Reynolds T. Issues remain for treating colorectal cancer. J Natl Cancer Inst. 1995 Apr 05;87(7):480. doi: 10.1093/jnci/87.7.480. PMID: 7707431.
Copy Download .nbib Format: NLM
The role of PDGFRA as a therapeutic target in young colorectal cancer patients.

Journal of translational medicine

Kim TW, Hong HK, Lee C, Kim S, Lee WY, Yun SH, Kim HC, Huh JW, Park YA, Joung JG, Park WY, Cho YB.
PMID: 34702313
J Transl Med. 2021 Oct 26;19(1):446. doi: 10.1186/s12967-021-03088-7.

BACKGROUND: Young patients with colorectal cancer (CRC) exhibit poor prognoses compared to older patients due to the difficulty in early diagnosis and treatment. However, the underlying molecular characteristics are still unclear.METHODS: We conducted a comprehensive analysis of 49 CRC...

Cite
Kim TW, Hong HK, Lee C, et al. The role of PDGFRA as a therapeutic target in young colorectal cancer patients. J Transl Med. 2021;19(1):446doi: 10.1186/s12967-021-03088-7.
Kim, T. W., Hong, H. K., Lee, C., Kim, S., Lee, W. Y., Yun, S. H., Kim, H. C., Huh, J. W., Park, Y. A., Joung, J. G., Park, W. Y., & Cho, Y. B. (2021). The role of PDGFRA as a therapeutic target in young colorectal cancer patients. Journal of translational medicine, 19(1), 446. https://doi.org/10.1186/s12967-021-03088-7
Kim, Tae Won, et al. "The role of PDGFRA as a therapeutic target in young colorectal cancer patients." Journal of translational medicine vol. 19,1 (2021): 446. doi: https://doi.org/10.1186/s12967-021-03088-7
Kim TW, Hong HK, Lee C, Kim S, Lee WY, Yun SH, Kim HC, Huh JW, Park YA, Joung JG, Park WY, Cho YB. The role of PDGFRA as a therapeutic target in young colorectal cancer patients. J Transl Med. 2021 Oct 26;19(1):446. doi: 10.1186/s12967-021-03088-7. PMID: 34702313; PMCID: PMC8546951.
Copy Download .nbib Format: NLM
The emergence of targetable pathways in colorectal cancer.

Clinical advances in hematology & oncology : H&O

Yu IS, Kopetz S.
PMID: 34928933
Clin Adv Hematol Oncol. 2021 Dec;19(12):774-783.

Colorectal cancer continues to be one of the leading causes of cancer-related morbidity and mortality globally. Despite an overall decreasing incidence of the disease, early-onset colorectal cancer is a growing concern. Fluoropyrimidine-based doublet chemotherapy has remained the backbone of...

Cite
Yu IS, Kopetz S. The emergence of targetable pathways in colorectal cancer. Clin Adv Hematol Oncol. 2021;19(12):774-783
Yu, I. S., & Kopetz, S. (2021). The emergence of targetable pathways in colorectal cancer. Clinical advances in hematology & oncology : H&O, 19(12), 774-783.
Yu, Irene S, and Kopetz, Scott. "The emergence of targetable pathways in colorectal cancer." Clinical advances in hematology & oncology : H&O vol. 19,12 (2021): 774-783.
Yu IS, Kopetz S. The emergence of targetable pathways in colorectal cancer. Clin Adv Hematol Oncol. 2021 Dec;19(12):774-783. PMID: 34928933.
Copy Download .nbib Format: NLM
[Selection of a molecule-target agent--present and prospect].

Nihon rinsho. Japanese journal of clinical medicine

Takahashi N, Hamaguchi T.
PMID: 22214008
Nihon Rinsho. 2011 Apr;69:482-6.

No abstract available.

Cite
Takahashi N, Hamaguchi T. [Selection of a molecule-target agent--present and prospect]. Nihon Rinsho. 2011;69:482-6
Takahashi, N., & Hamaguchi, T. (2011). [Selection of a molecule-target agent--present and prospect]. Nihon rinsho. Japanese journal of clinical medicine, 69482-6.
Takahashi, Naoki, and Hamaguchi, Tetsuya. "[Selection of a molecule-target agent--present and prospect]." Nihon rinsho. Japanese journal of clinical medicine vol. 69 (2011): 482-6.
Takahashi N, Hamaguchi T. [Selection of a molecule-target agent--present and prospect]. Nihon Rinsho. 2011 Apr;69:482-6. Japanese. PMID: 22214008.
Copy Download .nbib Format: NLM
[Ⅲ.Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2019 for the Treatment of Colorectal Cancer:Systemic Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy

Taniguchi H.
PMID: 31748479
Gan To Kagaku Ryoho. 2019 Nov;46(11):1709-1713.

No abstract available.

Cite
Taniguchi H. [Ⅲ.Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2019 for the Treatment of Colorectal Cancer:Systemic Therapy]. Gan To Kagaku Ryoho. 2019;46(11):1709-1713
Taniguchi, H. (2019). [Ⅲ.Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2019 for the Treatment of Colorectal Cancer:Systemic Therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 46(11), 1709-1713.
Taniguchi, Hiroya. "[Ⅲ.Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2019 for the Treatment of Colorectal Cancer:Systemic Therapy]." Gan to kagaku ryoho. Cancer & chemotherapy vol. 46,11 (2019): 1709-1713.
Taniguchi H. [Ⅲ.Japanese Society for Cancer of the Colon and Rectum(JSCCR)Guidelines 2019 for the Treatment of Colorectal Cancer:Systemic Therapy]. Gan To Kagaku Ryoho. 2019 Nov;46(11):1709-1713. Japanese. PMID: 31748479.
Copy Download .nbib Format: NLM
Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.

Japanese journal of clinical oncology

Hirano H, Takashima A, Hamaguchi T, Shida D, Kanemitsu Y.
PMID: 33205813
Jpn J Clin Oncol. 2021 Jan 01;51(1):10-19. doi: 10.1093/jjco/hyaa200.

Immunotherapy, especially immune checkpoint inhibitors, has revolutionized the standard-of-care of multiple types of tumors. For colorectal cancer, the clinical development of immune checkpoint inhibitors is mainly separated according to the status of microsatellite instability or mismatch repair in a...

Cite
Hirano H, Takashima A, Hamaguchi T, et al. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. Jpn J Clin Oncol. 2021;51(1):10-19doi: 10.1093/jjco/hyaa200.
Hirano, H., Takashima, A., Hamaguchi, T., Shida, D., Kanemitsu, Y. (2021). Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. Japanese journal of clinical oncology, 51(1), 10-19. https://doi.org/10.1093/jjco/hyaa200
Hirano, Hidekazu, et al. "Current status and perspectives of immune checkpoint inhibitors for colorectal cancer." Japanese journal of clinical oncology vol. 51,1 (2021): 10-19. doi: https://doi.org/10.1093/jjco/hyaa200
Hirano H, Takashima A, Hamaguchi T, Shida D, Kanemitsu Y. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. Jpn J Clin Oncol. 2021 Jan 01;51(1):10-19. doi: 10.1093/jjco/hyaa200. PMID: 33205813.
Copy Download .nbib Format: NLM
Letter to the Editor from Colle .

Journal for immunotherapy of cancer

Colle R, Andre T, Menu Y.
PMID: 34162716
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002997.

In their article, Fucà

Cite
Colle R, Andre T, Menu Y. Letter to the Editor from Colle . J Immunother Cancer. 2021;9(6)doi: 10.1136/jitc-2021-002997.
Colle, R., Andre, T., & Menu, Y. (2021). Letter to the Editor from Colle . Journal for immunotherapy of cancer, 9(6), . https://doi.org/10.1136/jitc-2021-002997
Colle, Raphael, et al. "Letter to the Editor from Colle ." Journal for immunotherapy of cancer vol. 9,6 (2021). doi: https://doi.org/10.1136/jitc-2021-002997
Colle R, Andre T, Menu Y. Letter to the Editor from Colle . J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002997. PMID: 34162716; PMCID: PMC8231023.
Copy Download .nbib Format: NLM
Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.

Cancer communications (London, England)

Zhou C, Jiang T, Li R, Yuan Y, Xie W, Huang X, Wang Q, Chang H, Chen G, Li Y, Zeng Z, Xiao W, Gao Y.
PMID: 34327863
Cancer Commun (Lond). 2021 Sep;41(9):921-924. doi: 10.1002/cac2.12199. Epub 2021 Jul 30.

No abstract available.

Cite
Zhou C, Jiang T, Li R, et al. Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. Cancer Commun (Lond). 2021;41(9):921-924doi: 10.1002/cac2.12199.
Zhou, C., Jiang, T., Li, R., Yuan, Y., Xie, W., Huang, X., Wang, Q., Chang, H., Chen, G., Li, Y., Zeng, Z., Xiao, W., & Gao, Y. (2021). Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. Cancer communications (London, England), 41(9), 921-924. https://doi.org/10.1002/cac2.12199
Zhou, Chengjing, et al. "Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis." Cancer communications (London, England) vol. 41,9 (2021): 921-924. doi: https://doi.org/10.1002/cac2.12199
Zhou C, Jiang T, Li R, Yuan Y, Xie W, Huang X, Wang Q, Chang H, Chen G, Li Y, Zeng Z, Xiao W, Gao Y. Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis. Cancer Commun (Lond). 2021 Sep;41(9):921-924. doi: 10.1002/cac2.12199. Epub 2021 Jul 30. PMID: 34327863; PMCID: PMC8441054.
Copy Download .nbib Format: NLM
The Role of Maintenance Therapy in Metastatic Colorectal Cancer.

JAMA oncology

Wang ZX, Liang F, Xu RH.
PMID: 32297912
JAMA Oncol. 2020 Jun 01;6(6):937. doi: 10.1001/jamaoncol.2020.0580.

No abstract available.

Cite
Wang ZX, Liang F, Xu RH. The Role of Maintenance Therapy in Metastatic Colorectal Cancer. JAMA Oncol. 2020;6(6):937doi: 10.1001/jamaoncol.2020.0580.
Wang, Z. X., Liang, F., & Xu, R. H. (2020). The Role of Maintenance Therapy in Metastatic Colorectal Cancer. JAMA oncology, 6(6), 937. https://doi.org/10.1001/jamaoncol.2020.0580
Wang, Zi-Xian, et al. "The Role of Maintenance Therapy in Metastatic Colorectal Cancer." JAMA oncology vol. 6,6 (2020): 937. doi: https://doi.org/10.1001/jamaoncol.2020.0580
Wang ZX, Liang F, Xu RH. The Role of Maintenance Therapy in Metastatic Colorectal Cancer. JAMA Oncol. 2020 Jun 01;6(6):937. doi: 10.1001/jamaoncol.2020.0580. PMID: 32297912.
Copy Download .nbib Format: NLM
Colorectal Cancer Subtypes - The Current Portrait.

Advances in experimental medicine and biology

Jordan P.
PMID: 30623362
Adv Exp Med Biol. 2018;1110:1-6. doi: 10.1007/978-3-030-02771-1_1.

Colorectal cancer (CRC) is one prominent example for how chemotherapy has been changing by moving from the use of general cytotoxic agents to more tumour-specific drugs. For example, antibody-based drugs neutralize a growth factor receptor protein on the surface...

Cite
Jordan P. Colorectal Cancer Subtypes - The Current Portrait. Adv Exp Med Biol. 2018;1110:1-6doi: 10.1007/978-3-030-02771-1_1.
Jordan, P. (2018). Colorectal Cancer Subtypes - The Current Portrait. Advances in experimental medicine and biology, 11101-6. https://doi.org/10.1007/978-3-030-02771-1_1
Jordan, Peter. "Colorectal Cancer Subtypes - The Current Portrait." Advances in experimental medicine and biology vol. 1110 (2018): 1-6. doi: https://doi.org/10.1007/978-3-030-02771-1_1
Jordan P. Colorectal Cancer Subtypes - The Current Portrait. Adv Exp Med Biol. 2018;1110:1-6. doi: 10.1007/978-3-030-02771-1_1. PMID: 30623362.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 15 entries